New protein arginine N-methyltransferase 5 (PRMT5) inhibitors are detailed in a Scinnohub Pharmaceutical Co. Ltd. patent and described as potentially useful for the treatment of cancer.

Scientists at Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have synthesized protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the ...

Bayer and Suzhou Puhe BioPharma Co.,Ltd., a clinical-stage biotechnology company, announced that they have entered into a global license agreement for Puhe BioPharma’s oral, small molecule PRMT5 ...

Tango Therapeutics (TNGX), a biotechnology company with a market capitalization of $190 million, has been making waves in the oncology space with its focus on developing PRMT5 inhibitors for solid ...

The companies have collaborated for Suzhou Puhe BioPharma’s oral, small molecule protein arginine N-methyltransferase 5 (PRMT5) inhibitor that selectively targets methylthioadenosine ...

Under the agreement, Bayer obtains an exclusive worldwide license to develop, manufacture and commercialize the MTA-cooperative PRMT5 inhibitor. Bayer has enrolled the first participant in a Phase ...